LAG-3 and TIM-3 are already the subject of clinical trials in the treatment of other cancers (e.g., melanoma, lung cancer, breast cancer), where their blockade leads to the activation of the immune response and increased therapy effectiveness. Here, HAVCR2 is linked to breast carcinoma.